Meta-Analysis
Copyright ©The Author(s) 2024.
World J Gastrointest Surg. Feb 27, 2024; 16(2): 571-584
Published online Feb 27, 2024. doi: 10.4240/wjgs.v16.i2.571
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flow chart of selecting studies for inclusion. RCT: Randomized controlled trial; IBD: Inflammatory bowel disease.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Network plot of included studies of proactive therapeutic drug monitoring vs conventional management with available direct comparisons for clinical remission. IFX: Infliximab; ADA: Adalimumab; IFX: Infliximab; CD: Crohn's disease; RCT: Randomized controlled trial; UC: Ulcerative colitis; IBD: Inflammatory bowel disease.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 League plot of proactive therapeutic drug monitoring vs conventional management efficacy in clinical remission outcome. aSignificant different. IFX: Infliximab; ADA: Adalimumab; IFX: Infliximab; CD: Crohn's disease; RCT: Randomized controlled trial; UC: Ulcerative colitis; IBD: Inflammatory bowel disease.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 League plot of proactive therapeutic drug monitoring vs conventional management outcomes. A: Need of surgery; B: Adverse events. aSignificant different. IFX: Infliximab; ADA: Adalimumab; IFX: Infliximab; CD: Crohn's disease; RCT: Randomized controlled trial; UC: Ulcerative colitis; IBD: Inflammatory bowel disease.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Cross-hair plot of pairwise and network meta-analysis outcomes of proactive therapeutic drug monitoring vs conventional management outcomes. A: Clinical remission; B: Adverse events. ADA: Adalimumab; IFX: Infliximab; CD: Crohn's disease; RCT: Randomized controlled trial; UC: Ulcerative colitis; IBD: Inflammatory bowel disease.